Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 30;3(1):e000112.
doi: 10.1136/bmjgast-2016-000112. eCollection 2016.

Management of hepatitis C genotype 4 in the directly acting antivirals era

Emma Hathorn  1 , Ahmed M Elsharkawy  1
Affiliations

Management of hepatitis C genotype 4 in the directly acting antivirals era

Emma Hathorn et al. BMJ Open Gastroenterol. .

Abstract

Genotype 4 chronic hepatitis C (G4 HCV) accounts for 13% of worldwide HCV infections; with 10 million people infected with the virus across the world. Up to the end of 2013, the only treatment option for G4 HCV was treatment with pegylated interferon and ribavirin for 24-48 weeks. Since late 2013, treatment of G4 HCV has been transformed by the licensing of many directly acting antiviral agents (DAA). It is an exciting time to be involved in the management of HCV generally and G4 particularly. Interferon-free DAA regimens are now a reality for G4 HCV. This review will highlight these developments and discuss the data behind the use of these drugs. It will also highlight future regimens that are likely to be available over the coming years.

Keywords: ANTIVIRAL THERAPY; GENOTYPE; HEPATITIS C.

PubMed Disclaimer

References

    1. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176–92. doi:10.1053/j.gastro.2014.03.003 - DOI - PubMed
    1. Foster GR. Shorter treatments for hepatitis C: another step forward? Lancet 2015;385:1054–5. doi:10.1016/S0140-6736(14)61600-7 - DOI - PubMed
    1. Feld JJ. The beginning of the end: what is the future of interferon therapy for chronic hepatitis C? Antiviral Res 2014;105:32–8. doi:10.1016/j.antiviral.2014.02.005 - DOI - PubMed
    1. Kohli A, Osinusi A, Sims Z, et al. . Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015;385:1107–13. doi:10.1016/S0140-6736(14)61228-9 - DOI - PMC - PubMed
    1. Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int 2015;35(Suppl 1):27–34 doi:10.1111/liv.12724 - DOI - PubMed

LinkOut - more resources